Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (1637)	7/21/2006 1:11:02 PM
From: Icebrg	Respond to of 1834

This is (was) a program which Neurocrine for all practical purposes seemed to have killed several years ago. Clearly, they saw no benefits continuing its development. Erik

To: zeta1961 who wrote (1637)	7/23/2006 1:10:28 PM
From: scaram(o)uche	Respond to of 1834

We've discussed this program, without much enthusiasm, for years. It was strange from the very beginning, as nbix licensed the IL-4 construct but another company (you've posted about the project several times... NeoPharma, or something like that) got the IL-13 construct from the same NIH lab. IL-13 covers both IL-13 and IL-4 receptors, so the nbix program seemed to come with a built-in "perhaps better" competitor, a sister molecule from the same NIH lab. Not a big loss, IMO and as Erik indicated. Glad to see a company carrying it forward, however.